Heterozygous factor VII deficiency and severe hemophilia A in the same kindred

1995 ◽  
Vol 6 (7) ◽  
pp. 676-679 ◽  
Author(s):  
A. Girolami ◽  
M. T. Sartori ◽  
C. Rossi ◽  
A. Cogo ◽  
P. Zerbinati
Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 3657-3657
Author(s):  
Ji Kyoung Park ◽  
Soon Yong Lee ◽  
Young Sil Park

Abstract Abstract 3657 Intracranial hemorrhage (ICH) is known to be a severe although uncommon complication of inherited bleeding disorder. A 12-year retrospective study was conducted to investigated the episodes of ICH in children with an inherited bleeding disorder who where followed by a regional hemophilia comprehensive center in South Korea. We review cases of ICH events in patients with inherited bleeding disorders in children and investigate characteristics, treatment, and prognosis. Between January 1998 and August 2010, a total of 13 ICHs in 9 patients were identified. ICHs were occurred for 7 patients with hemophilia A, one patient with hemophilia B, and one patient with factor VII deficiency. All patients were male and severe hemophilia A(2 patients); moderate hemophilia A(5 patients); moderate hemophilia B(1 patients). One of the patients with severe hemophilia A had inhibitors. The median age of patients was 6years 11months old. (range, 7 days≂f15 years old). Types of ICHs were 8 SDH, 2 EDH, 1 intracerebral with IVH, 1 intracerebral with SDH and 1 SDH with SAH. 8 cases were occurred spontaneously and 5 cases were occurred after traumatic events. Presenting symptoms were headache (6 events), seizure (2 events), vomiting (1 event), stuporous mentality (1 event), lethargy (1 event), irritability (1 event) but one patient with traumatic SDH had no symptom. Initial diagnostic modality was CT scan. One patient with severe hemophilia A who had inhibitors was initially treated with FEIBA® and controlled well. The remaining patients with hemophilia were treated with factor eight/nine concentrate. The patients with factor VII deficiency was treated with recombinant factor VIIa (Novoseven®). The patient with moderate hemophilia B required surgical evacuation. The mean duration of hospitalization was 12.8 days (range, 3–25 days). ICH was the first significant bleeding event in 3 patients – one with moderate hemophilia A, aged 7 days, and one with moderate hemophilia A, aged 5months, and one with factor VII deficiency, aged 1months. The median follow-up duration was 73 months (range, 4–149 months). Two younger patients had complication with long term sequale like hydrocephalus, cerebral palsy, and epilepsy. For one patient, antibody to factor VIII was developed due to factor administration. ICH can occur in patient with a severe inherited bleeding disorder and also in patients with moderate hemophilia. Younger patients with ICH may have poor prognosis and neurologic sequale more frequently. Symptoms of younger patients was atypical so their parental recognition and medical diagnosis delayed. The median duration between onset of symptom and administration of factor is 2.6 days(range, 0–8 days). Delayed administration of factor caused the patients to have long term sequale. Rapid and appropriate factor administration is important to treatment course and prognosis. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 3968-3968
Author(s):  
Robert Chen ◽  
Seligman Paul ◽  
Justin Call ◽  
Brenda Riske ◽  
Ruth Ann Kirschman ◽  
...  

Abstract Orthotopic liver transplantation (OLT) is an effective treatment for both hepatitis C associated cirrhosis, hepatocellular carcinoma, and hemophilia A. Factor VIII activity usually increases into the normal range. Only a few patients with hemophilia complicated by an inhibitor have undergone OLT with both successful outcomes and uncontrolled bleeding being reported. We report early results of OLT in a middle-aged white male severe hemophilia A patient with a history of a high responding inhibitor (historical high - 70 Bethesda units) who had been on immune tolerance for greater than 10 years prior to transplant. A regimen of 40 u/kg of Factor VIII three times per week successfully suppressed inhibitor titers to less than 2 Bethesda units in the previous years. Hand surgery was managed with Factor VII infusions in the year prior to OLT with good results. At the time of transplantation, his inhibitor titer was 0.7 B.U. Due to his history of non-linear kinetics with factor VIII infusion, (5% of a dose remaining at 24 hours), frequent bolus dosing during surgery was employed. He received 10,500 units (116 units/kg) prior to the incision with smaller doses repeated every 2–4 hours. During the operation and the 24 hr immediately post op he required another 27,300 units (300 units/kg) of factor VIII infusion to maintain activity between 61–122%. On post op day 1 he required 46 units/kg to keep activity between 60.2–108%. On post op day 2 he required 35 units/kg to keep activity between 36.8–68.4%. His immunosuppresion included tacrolimus, mycophenolate, and solumedrol taper of 120 mg on day 2, 80 mg on day 3, 40 mg on day 4, and 20 mg day 5. From day 6 to day 8, his total bilirubin increased to 15 and his requirement for Factor VIII also increased to 70 units/kg daily for 3 days to keep his activity between 33.1% to 71.2%. His immunosuppression was increased because of possible acute rejection and solumedrol 500 mg IV was given daily for 3 days. On day 9 his requirement for factor decreased to 11.6 units/kg daily for 4 additional days. Solumedrol was tapered off to prednisone 10 mg po daily. On day 13 post operation, Factor VIII replacement was stopped and his activity was 56.8%, which gradually rose to 81% on day 25. We conclude: Orthotopic liver transplantation was successful in a hemophilia A inhibitor patient on long term immune tolerance. Factor VIII production by the transplanted liver suppressed the inhibitor and normalized Factor VIII activity up to 4 weeks post transplant. Close follow-up will be required.


ILAR Journal ◽  
2009 ◽  
Vol 50 (2) ◽  
pp. 144-167 ◽  
Author(s):  
T. C. Nichols ◽  
A. M. Dillow ◽  
H. W. G. Franck ◽  
E. P. Merricks ◽  
R. A. Raymer ◽  
...  

1961 ◽  
Vol 264 (21) ◽  
pp. 1078-1082 ◽  
Author(s):  
Lamont W. Gaston ◽  
Bernard F. Mach ◽  
William S. Beck

2015 ◽  
Vol 87 (9) ◽  
Author(s):  
Andrzej B. Szczepanik ◽  
Wojciech P. Dąbrowski ◽  
Anna M. Szczepanik ◽  
Konrad Pielaciński ◽  
Wojciech Jaśkowiak

AbstractIn cirrhotic hemophilia patients bleeding from esophageal varices is a serious clinical condition due to congenital deficiency of clotting factors VIII or IX, decreased prothrombin synthesis and hypersplenic thrombocytopenia. In hemophiliac with high-titer inhibitor bypassing therapy is required with activated prothrombin complex concentrates (aPCC) or recombinant activated coagulation factor VII (rFVIIa). Doses and duration treatment with these agents following endoscopic treatment of esophageal varices have not been yet established.Authors report the first case of a severe hemophilia A patient with high titer inhibitor (40 BU) treated with repeated injection sclerotherapy. The patient was admitted with symptoms of massive esophageal variceal hemorrhage ceased with emergency sclerotherapy. Bypassing therapy was administered with aPCC at initial dose of 72.5 U/kg and then with average daily dose of 162 U/kg through 5 days. To achieved a total eradication of esophageal varices the patient was then subjected to four elective sclerotherapy procedures. Two were covered by aPCC with daily dose of 120 U/kg and 145 U/kg for 4 and 3 days respectively and the following two procedures were covered by rFVIIa with the initial dose of 116 µg/kg and the next doses of 87 µg/kg administered every 3 hours in procedure day and every 4 hours on the next two days. During all procedures excellent hemostasis was achieved and no hemorrhagic or thromboembolic complications were observed. Bypassing regimen therapy with aPCC and rFVIIa we applied have been shown to be safe and effective in this patient subjected to sclerotherapy procedures.


Sign in / Sign up

Export Citation Format

Share Document